# Test Results: statistics/interpretation-brainstorming.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** statistics/interpretation-brainstorming.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I have completed an experiment and am interpreting the results. I want to think through possible interpretations thoroughly.

Research question: Does fecal microbiota transplantation from lean donors improve metabolic outcomes in obese mice?

Experimental design (brief):
- 3 groups (n=10 each): Control (PBS), FMT from lean donors, FMT from obese donors
- High-fat diet-induced obese mice, 8 weeks treatment
- Measured: body weight, fasting glucose, microbiome composition

Results summary:
- Main finding: FMT-lean group had significantly lower fasting glucose than Control (p=0.01) and FMT-obese (p=0.03)
- Effect size: Mean glucose 145 vs 180 mg/dL (FMT-lean vs Control)
- Body weight: No significant differences between any groups
- Microbiome: FMT-lean group showed higher diversity and different community composition
- The donor-derived taxa were detectable in recipients
- Unexpected: FMT-obese group showed slightly (non-significant) lower glucose than Control

My initial interpretation: Lean-donor microbiota transfers metabolically beneficial effects to obese recipients, potentially through specific bacterial taxa that improve glucose regulation.

Task: Help me think through these results critically:

1. **Support for initial interpretation**: What evidence supports my interpretation? How strong is it?

2. **Alternative interpretations**: What other explanations could produce these results? For each alternative:
   - What would it predict?
   - How could I distinguish it from my interpretation?

3. **Potential confounds**: What factors might have influenced the results that aren't captured in my interpretation?

4. **Limitations to acknowledge**: What caveats should I include when presenting these findings?

5. **Questions for follow-up**: What additional experiments or analyses would strengthen the interpretation?

6. **What the results don't show**: What conclusions would be overreach?

Constraints:
- Be genuinely critical—I want to anticipate reviewer objections
- Don't just agree with my interpretation; actively generate alternatives
- Distinguish between plausible alternatives and unlikely ones
- Focus on scientific interpretation, not just statistical significance
````

## Model Output
````


Below is a structured, “devil’s‑advocate” walk‑through of your data.  I have tried to stay strictly within the realm of biological plausibility (no “magic” explanations) while still surfacing every reasonable alternative that a reviewer might raise.  Feel free to copy‑paste the sections into a manuscript discussion or a rebuttal letter.

---

## 1.  Support for the Initial Interpretation  

| Observation | Why it favours the “lean‑donor microbiota → improved glucose” view | Strength of evidence |
|-------------|---------------------------------------------------------------------|----------------------|
| **FMT‑lean ↓ fasting glucose** (145 vs 180 mg/dL; p = 0.01 vs PBS, p = 0.03 vs FMT‑obese) | The direction of change matches the hypothesis that a lean‑associated community can confer a metabolic benefit. The effect size (~35 mg/dL ≈ 20 % reduction) is biologically meaningful in murine HFD models. | Moderate‑strong (statistically significant, reproducible across two comparisons). |
| **Higher α‑diversity & shifted community composition** in FMT‑lean recipients | Lean donors are typically more diverse; engraftment of that diversity is a prerequisite for functional transfer. | Moderate (diversity is correlative; does not prove causality). |
| **Donor‑derived taxa detectable** in recipients | Confirms that the inoculum actually engrafted (at least at the level of detection used). | Strong for engraftment, weak for functional relevance (detectability ≠ activity). |
| **No weight change** across groups | Suggests the glucose benefit is not secondary to reduced adiposity or food intake, supporting a direct microbial effect on glucose homeostasis. | Moderate (weight is a crude proxy; subtle changes in fat distribution or food intake could be missed). |
| **FMT‑obese trend toward lower glucose** (non‑significant) | If anything, the obese donor microbiota is *not* worsening glucose; this makes a deleterious “obese‑microbiota” effect less likely and leaves room for a neutral or mildly beneficial effect of the lean community. | Weak (trend only). |

**Overall:** The data are consistent with a causal link, but the evidence is still largely *associational* (phenotype + microbiome shift) and rests on a single metabolic read‑out.  The strength is enough to generate a hypothesis, but not sufficient to claim mechanistic proof.

---

## 2.  Alternative Interpretations  

Below each alternative I list (a) what it would predict beyond what you already measured, and (b) a concrete experiment or analysis that could discriminate it from your primary hypothesis.

| # | Alternative hypothesis | Core idea | Predictions (beyond current data) | How to test / distinguish |
|---|------------------------|----------|-----------------------------------|----------------------------|
| **A** | **Procedure‑related stress or handling differences** (e.g., gavage volume, timing, operator) | The act of delivering a fecal slurry (vs PBS) could alter stress hormones, gut motility, or circadian feeding patterns, indirectly improving glucose. | • FMT‑lean and FMT‑obese groups should show similar physiological changes (e.g., corticosterone, gut transit time) if the effect is procedural.<br>• No specific microbial signature would be required. | • Measure stress markers (corticosterone, heart‑rate variability) and feeding behavior across groups.<br>• Include a “sham‑FMT” control: gavaged with sterile filtrate from lean donor (bacteria removed) to see if the effect persists. |
| **B** | **Donor‑specific soluble factors (metabolites, bile acids, bacteriophages) rather than live bacteria** | The filtrate (or even the pellet after low‑speed centrifugation) may contain bioactive molecules (SCFAs, secondary bile acids, vitamins, phage‑encoded enzymes) that survive the transplant and act on host metabolism. | • FMT‑lean effect should be observable even after filtering out bacteria (0.22 µm) or after antibiotic‑killing the inoculum.<br>• Metabolomic profiling of the inoculum would show lean‑specific metabolites (e.g., higher butyrate, lower secondary bile acids). | • Prepare three inocula: (i) whole stool, (ii) bacteria‑free filtrate, (iii) heat‑killed bacteria.<br>• Test each for glucose effect.<br>• Perform untargeted metabolomics on donor stools and on recipient plasma/cecum. |
| **C** | **Microbiome‑independent immune modulation by donor‑derived microbial-associated molecular patterns (MAMPs)** | Certain microbial components (e.g., LPS, peptidoglycan) from lean donors could tone down systemic inflammation, improving insulin signaling without requiring engraftment of live taxa. | • Lean donor stool would have a distinct MAMP profile (e.g., lower LPS potency, different TLR agonists).<br>• Recipients would show reduced inflammatory cytokines (TNF‑α, IL‑6, MCP‑1) irrespective of engraftment level. | • Quantify plasma and tissue cytokines.<br>• Use TLR‑deficient mice (e.g., TLR4‑KO) to see if the glucose benefit disappears.<br>• Compare MAMP activity (e.g., HEK‑Blue TLR reporter assay) of lean vs obese donor stools. |
| **D** | **Batch or cage effects (environmental microbiota transfer)** | Mice housed together share microbes via coprophagy; if the FMT‑lean cages happened to have a slightly different baseline environment (e.g., bedding, water bottle), the observed difference could be due to horizontal transfer rather than the inoculum. | • FMT‑lean mice would show greater similarity to each other *and* to cage‑mates not receiving the transplant (if any).<br>• Sequencing of sentinel (untreated) mice in the same rack would reveal a lean‑like shift. | • Include sentinel mice (no gavage) in each rack.<br>• Perform PERMANOVA on cage as a factor.<br>• If cage explains a large proportion of variance, re‑randomize mice across cages in a repeat experiment. |
| **E** | **Regression to the mean / random variability** | With n = 10 per group, a single outlier can shift the mean; the observed difference may be a fluke, especially given the modest p‑values. | • Repeating the experiment would produce a distribution of effect sizes centered around zero (or a smaller effect).<br>• The confidence interval around the mean difference would be wide. | • Perform a power‑simulation: given observed variance, what is the probability of obtaining p < 0.05 by chance?<br>• Increase n in a follow‑up to see if the effect persists and narrows the CI. |
| **F** | **Donor variability (lean donor not truly “lean” metabolically)** | The lean donor used may have idiosyncratic traits (e.g., low-grade inflammation, altered bile acid pool) that are not captured by body weight alone, and those traits drive the effect. | • Other lean donors would not reproduce the glucose improvement.<br>• Phenotyping the donor (glucose tolerance, insulin, hepatic lipids) would reveal an atypical metabolic profile. | • Repeat FMT with multiple independent lean donors (≥3) and test whether the effect is donor‑consistent.<br>• Characterize donor metabolism before stool collection. |
| **G** | **Antibiotic carry‑over from donor preparation** | If the lean donor stool was processed with antibiotics (e.g., to reduce pathogens) while the obese donor stool was not, residual antibiotics could affect the recipient’s gut flora and glucose metabolism. | • FMT‑lean recipients would show a transient reduction in total bacterial load (qPCR 16S) shortly after gavaging.<br>• Metabolite profiles would show antibiotic‑related shifts (e.g., decreased bile acid deconjugation). | • Measure 16S copy number in feces at 24 h, 72 h, and 1 wk post‑gavage.<br>• Include an antibiotic‑control group ( gavaged with sterile PBS + same antibiotic dose). |
| **H** | **Sex‑specific or age‑specific effects not accounted for** | If all mice were, say, male, the observed effect could be sex‑limited; or if the mice were at a particular age where microbiota plasticity is high, the result may not generalize. | • Repeating the experiment in females or older mice would yield a different (perhaps null) outcome. | • Run a parallel cohort with female mice or aged mice; compare effect sizes. |

**Plausibility ranking (subjective, based on typical microbiome work):**  
Most plausible: **B** (soluble metabolites), **C** (immune modulation via MAMPs), **A** (procedural stress).  
Less plausible but still worth checking: **D** (cage effects), **F** (donor variability), **E** (random variability).  
Unlikely unless you have evidence of procedural mishaps: **G** (antibiotic carry‑over), **H** (sex/age) – but they are easy to rule out.

---

## 3.  Potential Confounds Not Captured in Your Interpretation  

| Confound | Why it could bias the result | How to assess / mitigate |
|----------|-----------------------------|--------------------------|
| **Food intake / energy expenditure** | Even if body weight is unchanged, subtle differences in caloric intake or activity could affect glucose. | Measure daily food consumption (pair‑feeding if needed) and indirect calorimetry (VO₂, VCO₂, locomotion). |
| **Circadian timing of sampling** | Fasting glucose varies across the light‑dark cycle; if groups were sampled at different times, apparent differences could be artefactual. | Standardize the time of bleed (e.g., ZT4–ZT6) and record exact timestamps. |
| **Stress from gavage** | Repeated oral gavage can elevate corticosterone, which acutely raises glucose; differences in gavage skill or volume between groups could create bias. | Blind the operator to group, use identical gavage volumes, and measure stress hormones. |
| **Microbiota transfer via coprophagy** | Mice eat each other’s feces; cross‑contamination could dilute or spread the inoculum, especially if cages are not separated by filter tops. | Use individually ventilated cages (IVCs) with filter tops, or house each mouse singly during the intervention period. |
| **Batch effects in DNA extraction / sequencing** | If library prep differed between groups (e.g., different dates), apparent compositional shifts could be technical. | Randomize samples across extraction batches, include extraction blanks, and use spike‑in controls for absolute quantification. |
| **Glucose assay variability** | Glucometer or enzymatic assay drift can produce ~5‑10 % variation; if not blinded, could bias results. | Run samples in duplicate, randomize plate layout, and include internal standards. |
| **Sex hormone cycle (if females)** | Estrous cycle influences glucose tolerance. | If using females, track estrous stage or ovariectomize to remove hormonal fluctuation. |
| **Host genetics drift** | Even inbred strains can acquire subtle mutations over generations; if groups were sourced from different breeding colonies, background differences could exist. | Confirm that all mice originate from the same breeding pair or perform speed‑congential backcrossing. |
| **Donor stool storage / freeze‑thaw cycles** | Different handling (e.g., number of freeze‑thaw cycles) could affect viability of bacteria or stability of metabolites. | Standardize stool processing (aliquot, single freeze‑thaw, same storage temperature) for all donors. |

---

## 4.  Limitations to Acknowledge (When Presenting)

1. **Sample size** – n = 10 per group provides limited power to detect modest effects and makes the estimates sensitive to outliers.  
2. **Single metabolic read‑out** – Only fasting glucose was measured; no insulin tolerance test, pyruvate tolerance test, or hyperinsulinemic‑euglycemic clamp data to confirm improved insulin sensitivity.  
3. **No direct assessment of engraftment efficacy** – Detection of donor taxa does not quantify their relative abundance or metabolic activity; low‑level detection may not be functionally relevant.  
4. **Short‑term intervention** – 8 weeks may not capture longer‑term adaptations or potential late‑onset adverse effects.  
5. **Lack of mechanistic read‑outs** – No data on SCFAs, bile acids, gut permeability, inflammation, or hepatic lipid metabolism, which are plausible mediators.  
6. **Potential donor‑specific effects** – Results are tied to one lean and one obese donor; generalization to other donors is unknown.  
7. **Environmental confounders** – Housing, handling, and circadian timing were not explicitly reported as controlled variables.  
8. **Sex limitation** – If only one sex was used, the findings may not extrapolate to the opposite sex.  
9. **No pair‑feeding or indirect calorimetry** – Weight stability does not guarantee equal energy balance.  
10. **Statistical approach** – p‑values are reported without correction for multiple comparisons (e.g., if other metabolites or taxa were tested).  

When you discuss the data, frame the conclusion as “*consistent with* a beneficial metabolic effect of lean‑donor microbiota, but *causality remains to be demonstrated*.”

---

## 5.  Questions for Follow‑Up (Experiments / Analyses)

| Goal | Suggested experiment | What it would add |
|------|----------------------|-------------------|
| **Confirm engraftment & activity** | Quantitative PCR or digital droplet PCR for key donor taxa; metatranscriptomics to assess gene expression (e.g., butyrate synthesis pathways). | Shows that donor microbes are not just present but metabolically active. |
| **Test soluble factor hypothesis** | Prepare bacteria‑free filtrate (0.22 µm) and heat‑killed stool from lean donor; gavaged recipients; measure glucose. | If effect persists, points to metabolites, phages, or MAMPs rather than live bacteria. |
| **Immune mediation** | Measure plasma cytokines, gut intra‑epithelial lymphocyte phenotypes; repeat FMT in TLR4‑KO or MyD88‑KO mice. | Determines whether innate immune signaling is required. |
| **Metabolite profiling** | Targeted LC‑MS for SCFAs, secondary bile acids, tryptophan metabolites, and untargeted metabolomics on feces, plasma, liver. | Identifies candidate molecules that differ between lean‑ and obese‑FMT recipients. |
| **Functional microbiome transfer** | Germ‑free mice colonized with feces from lean‑FMT recipients vs obese‑FMT recipients vs control; phenotype. | Provides a causality test that isolates the microbiota from procedural variables. |
| **Dose‑response & durability** | Vary FMT frequency (single bolus vs weekly) and duration (4, 8, 12 weeks); track glucose over time and after wash‑out. | Establishes whether effect is sustained, dose‑dependent, and reversible. |
| **Sex & age extension** | Repeat in female mice and in aged (12‑month) HFD mice. | Tests generalizability. |
| **Pair‑feeding / indirect calorimetry** | Monitor food intake, energy expenditure, respiratory exchange ratio. | Rules out covert changes in energy balance as driver of glucose improvement. |
| **Microbiome‑host interaction mapping** | Correlate specific taxa or functional pathways (e.g., butyrate synthesis genes) with glucose levels using mixed‑model or machine‑learning approaches. | Moves beyond correlation toward predictive biomarkers. |
| **Control for procedural stress** | Include a “sham‑gavage” group receiving sterile PBS via the same gavage schedule; measure corticosterone. | Isolates stress effects of the procedure itself. |

---

## 6.  What the Results **Do Not** Show (Overreach to Avoid)

| Overstated claim | Why it’s not supported |
|------------------|------------------------|
| “Lean‑donor microbiota *causes* improved glucose tolerance.” | Causality not proven; alternative mechanisms (metabolites, immune modulation, stress) remain viable. |
| “The observed glucose improvement is *independent* of weight change.” | Weight was measured only as total body mass; changes in fat distribution, lean mass, or food intake could still be present and affect glucose. |
| “Specific bacterial taxa identified are *responsible* for the effect.” | Only community‑level shifts were reported; no functional validation (e.g., gavage of isolated strains). |
| “FMT from obese donors is metabolically neutral or beneficial.” | The non‑significant trend is insufficient to claim neutrality; a larger study could reveal a harmful or beneficial effect. |
| “The microbiome changes observed will persist after cessation of FMT.” | No follow‑up after stopping treatment; the engraftment may be transient. |
| “The effect will translate to humans.” | Murine HFD model, single donor, and invasive gavage limit direct translational inference. |
| “The observed microbiome diversity increase *directly* drives the metabolic benefit.” | Diversity is a correlative marker; low‑diversity communities can also be beneficial, and high diversity can be neutral or deleterious. |
| “Any differences in fasting glucose are due to the microbiota *alone*.” | Host genetics, stress, circadian timing, and procedural variables were not fully controlled. |

---

### Bottom Line for Your Discussion

- **Strengths:** Clear, statistically significant lowering of fasting glucose with lean‑donor FMT, accompanied by a distinct, more diverse microbiome that engrafts.
- **Weaknesses & Open Questions:** Single metabolic phenotype, modest sample size, lack of mechanistic read‑outs, and several plausible non‑microbiological confounds.
-
````

## Assessment
_To be completed by a human reviewer. Do not mark Pass without reading the output._

### Task Achievement
- **Achieved:** [Yes / No / Partial]
- **Notes:**

### Constraint Compliance
- **All constraints respected:** [Yes / No]
- **Violations noted:**

### Failure Modes
- **Failure modes observed:** [None / list]
- **Mitigation effectiveness:**

### Output Format
- **Format correct:** [Yes / No]
- **Deviations:**

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
